Science Editor
For resistance, the attention goes to targeted cancer drugs.
Drugs targeting Bcr-Abl kinase, for example, are now on their third generation.
And for drugs like PLX-4032, reports of spectacular effects in the clinic are tempered by concurrent reports that resistance to them may develop rapidly in the majority of patients.
But resistance also develops to nontargeted agents, and two recent papers gave new insights into how it does, and how to deal with it.
The difference between targeted and nontargeted agents is partly a semantic one, or, as scientist Ingrid Wertz told BioWorld Insight, "'nontargeted agent' is a relative term."
Older agents such as Taxol were perhaps not designed with a specific molecular target in mind, but neither are …
No comments:
Post a Comment